Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
??? $CYTX 0.49 0.00 0.00 45,931 0.53 0.54
Close watch, $TROV 0.98 0.275 +39.01 773,850 1.00 1.03
Volume alert, $GSAT 1.66 0.00 0.00 2,052,646 1.68 1.69
Thanks buddy!
Hey, Thanks for the alert. How have you been?
Welcome to the board, Hope all is well!
Good morning, Bought back in $ONCI
Hey buddy, Everything with you?
I'm going away to RI sat. for a week.
Thanks again for $ONCI alert!
Close up 32% yesterday, $ANTH 1.90 0.00 0.00 17,893 2.00 2.05
On news, $GEVO 0.5952 0.00 0.00 201,179 0.65 0.66
Gevo to Supply Jet Fuel to Virgin Australia at Brisbane Airport in Australia
13 minutes ago - DJNF
Gevo to Supply Jet Fuel to Virgin Australia at Brisbane Airport in Australia
Flights Expected to be Flown through the End of 2018
ENGLEWOOD, Colo., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ:GEVO), announced today that it expects to supply its renewable alcohol-to-jet fuel (ATJ) to the Virgin Australia Group, a leading Australian airline group. The Virgin Australia Group will be responsible for coordinating the purchase, supply and blending of the ATJ into the fuel supply system at Brisbane Airport in Queensland, Australia. Gevo's ATJ is expected to be blended with traditional jet fuel and supplied on flights departing Brisbane Airport, including Virgin Australia flights. It is currently contemplated that Gevo will ship the first gallons of ATJ to the Virgin Australia Group in October 2017.
Gevo will supply the ATJ from its hydrocarbon plant based in Silsbee, Texas. The ATJ is derived from isobutanol produced at its commercial isobutanol plant located in Luverne, Minnesota (the "Luverne Facility").
Gevo is looking to expand its isobutanol production capabilities at the Luverne Facility to enable larger production volumes of its ATJ in the future. Gevo has a goal in 2017 of obtaining binding supply contracts for a combination of isobutanol and hydrocarbon products (ATJ and isooctane) equal to at least 50% of the capacity of the anticipated expanded Luverne Facility. These supply contracts are expected to form the basis on which Gevo would set the specific configuration of the Luverne Facility in terms of end product mix between isobutanol, ATJ and isooctane.
The Queensland government is supporting the arrangement as a first step in the development of a renewable jet fuel production industry in the state. Queensland is looking to leverage carbohydrate-based feedstocks, abundant to its local agricultural sector, to support the build-out of renewable jet fuel production plants in the future. Gevo is well positioned to play a role in this growth, as the company believes its ATJ is cost advantaged in comparison to other renewable jet alternatives derived from carbohydrate-based feedstocks.
Virgin Australia Group Chief Executive Officer John Borghetti said: "This initiative builds on Virgin Australia's commitment to be a leader in the commercialization of the sustainable aviation fuel industry in Australia. The project announced today is critical to testing the fuel supply chain infrastructure in Australia to ensure that Virgin Australia and Brisbane Airport are ready for the commercial supply of these exciting fuels."
"Biojet is fast becoming a staple of the aviation industry, and Brisbane is joining major airports such as Los Angeles and Oslo in embracing a sustainable aviation future. Although the aviation biojet fuel sector is quite new, there has been more than a decade of work behind it and hundreds of thousands of hours of fuel testing to prove the fuels are compatible with fossil based fuels. The first aviation biojet fuels were approved for commercial flights in 2011," said Queensland Premier Annastacia Palaszczuk.
"We are excited to work in partnership with Virgin Australia, the Queensland government and the Brisbane Airport Corporation to enable flights out of the Brisbane Airport using our ATJ. We believe Queensland offers huge potential for low-cost, biomass-based feedstocks to produce biofuels. When I visited Queensland last year for the Biofutures Industry Forum, I discovered the depth and diversity of its agriculture sector. It really opened our eyes to Queensland's potential for sustainable aviation fuels based on Gevo's ATJ technology," added Dr. Patrick Gruber, Gevo's Chief Executive Officer.
About Gevo
Gevo is a renewable technology, chemical products, and next generation biofuels company. Gevo has developed proprietary technology that uses a combination of synthetic biology, metabolic engineering, chemistry and chemical engineering to focus primarily on the production of isobutanol, as well as related products from renewable feedstocks. Gevo's strategy is to commercialize bio-based alternatives to petroleum-based products to allow for the optimization of fermentation facilities' assets, with the ultimate goal of maximizing cash flows from the operation of those assets. Gevo produces isobutanol, ethanol and high-value animal feed at its fermentation plant in Luverne, Minnesota. Gevo has also developed technology to produce hydrocarbon products from renewable alcohols. Gevo currently operates a biorefinery in Silsbee, Texas, in collaboration with South Hampton Resources Inc., to produce renewable jet fuel, octane, and ingredients for plastics like polyester. Gevo has a marquee list of partners including The Coca-Cola Company, Toray Industries Inc. and Total SA, among others. Gevo is committed to a sustainable bio-based economy that meets society's needs for plentiful food and clean air and water.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include statements relating to the commercial flights to be flown by Virgin Australia, Gevo's supply of ATJ, Gevo's plans and goals, including its plans to expand the Luverne Facility, the Queensland government's plans to develop the renewable jet fuel production industry and the properties of Gevo's ATJ, are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2016, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.
Media Contact
David Rodewald
The David James Agency, LLC
+1 805-494-9508
gevo@davidjamesagency.com
Investor Contact
Shawn M. Severson
EnergyTech Investor, LLC
+1 415-233-7094
gevo@energytechinvestor.com
@ShawnEnergyTech
www.energytechinvestor.com
(END) Dow Jones Newswires
October 03, 2017 09:00 ET (13:00 GMT)
News, $PERI 1.15 0.00 0.00 74,416 1.16 1.18
Perion's Undertone Division Named as a Snapchat Creative Partner
1 hour 20 minutes ago - DJNF
This Partnership Fortifies Perion's Growth Strategy, Via Undertone, Its Creative Advertising Division
TEL AVIV & NEW YORK--(BUSINESS WIRE)--October 03, 2017--
Perion Network Ltd. (NASDAQ: PERI) announced that Undertone, its creative advertising division and a leader in engaging digital advertising experiences for brands and publishers, has been named an official Snapchat Creative Partner. As a Snapchat Creative Partner, Undertone has been recognized for its outstanding ability to bring its dynamic creative to the Snapchat platform.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171003005742/en/
Doron Gerstel, Perion's CEO commented, "This is a strategic partnership for Perion, adding another layer to our creative advertising division. For the last 16 years, Undertone has been helping the world's most recognizable brands deliver engaging digital ad experiences to drive business results. We are honored that Snapchat has recognized our work and included Undertone as a part of the elite group of partners."
The Snapchat platform offers brands a number of creative capabilities, including gaming, interactive video, image and video carousels, and user-customizable fields. Undertone has already partnered with brands like Unify Water and Niagara to help them deliver high impact creative that taps into the unique functions and features of the Snapchat platform.
"This partnership underlines our commitment to cross-platform creativity and helping brands connect with consumers however they consume content," said Mike Pallad, President of Undertone. "With 173 million daily users around the world, Snapchat represents an important avenue for brands. We are proud that Snapchat has recognized our commitment to delivering impactful creative for our clients."
About Perion Network Ltd.:
Perion is a global technology company that delivers advertising solutions to brands and publishers. Perion is committed to providing data-driven execution, from high-impact ad formats to branded search and a unified social and mobile programmatic platform. More information about Perion may be found at www.perion.com, and follow Perion on Twitter@perionnetwork.
Forward Looking Statements
This press release contains historical information and forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of Perion. The words "will", "believe," "expect," "intend," "plan," "should" and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of Perion with respect to future events and are subject to risks and uncertainties. Many factors could cause the actual results, performance or achievements of Perion to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, among others, the failure to realize the anticipated benefits of companies and businesses we acquired and may acquire in the future, risks entailed in integrating the companies and businesses we acquire, including employee retention and customer acceptance; the risk that such transactions will divert management and other resources from the ongoing operations of the business or otherwise disrupt the conduct of those businesses, potential litigation associated with such transactions, and general risks associated with the business of Perion including intense and frequent changes in the markets in which the businesses operate and in general economic and business conditions, loss of key customers, unpredictable sales cycles, competitive pressures, market acceptance of new products, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, whether referenced or not referenced in this press release. Various other risks and uncertainties may affect Perion and its results of operations, as described in reports filed by the Company with the Securities and Exchange Commission from time to time, including its annual report on Form 20-F for the year ended December 31, 2016 filed with the SEC on March 7, 2017. Perion does not assume any obligation to update these forward-looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171003005742/en/
CONTACT: Perion Network Ltd.
Investor relations
Vicky Batkin
+972 (73) 398-1000
perion.investor.relations@perion.com
Source: Perion Network LTD.
SOURCE: Perion Network Ltd.
Copyright Business Wire 2017
(END) Dow Jones Newswires
October 03, 2017 07:00 ET (11:00 GMT)
It will be today, Go $ABVG!
Have a great weekend everyone!
Good morning curly and $ABVGers!
GM $ABVGers, More great day's are coming!
? $OPGN 0.3285 0.00 0.00 10,869 0.3301 0.3499
On close watch!
Glad you found the new dip & rip board.
Soon i hope we can get this board hopping.
We can and will all make money together.
Thanks for your support, Have fun and god bless!
$ABVG # 9 on ihub!
Great day's ahead for $ABVG. Hoping for a big run!
Bottom ? $GNCA 1.25 0.00 0.00 28,082 1.30 1.35
Person marked you!
Thank you, I have been so busy with other business.
Its been hard to devote alot of time here, Soon i hope.
Good luck & best to you!
GNCA 1.75 -3.58 -67.17 2,684,375 1.75 1.76
Close watch, $GNCA 2.24 -3.09 -57.97 187,894 2.20 2.24
Nice, Alerted on 9/21 $TEUM 1.06 0.00 0.00 170,673 1.45 1.50
$STAF 0.98 0.14 +16.67 437,399 0.961 0.98
Thanks for the heads up, on $QBAN buddy!
I bought $QBAN @ .0009 this morning!
Thanks, Here are a few i got in early. $BLDV $NECA $SNMN
Back in $FUTL at these prices!
Thanks again Pharaoh, $SNMN!
Hey buddy, First thank you. Hope all is well.
I'm doing reall well in pennies, right now. (AWESOME)
$TEUM 1.03 0.00 0.00 19,100 1.16 1.20
( TEUM ) With $4,000,000 Multi-Year Contract, Pareteum Provides Mobility to the $9 Billion Global Contact Center Market
17 minutes ago - DJNF
Provides Mobile Connectivity for Fortune 500 Businesses' API-Driven Online Sales and Marketing Programs
NEW YORK, NY/ ACCESSWIRE / September 21, 2017 / Pareteum Corporation (NYSE American: TEUM) ("Pareteum" or the "Company"), the rapidly growing mobile Cloud Communications Platform company, today announced it has been awarded a contract for its Global Mobility Cloud services from one of the world's leading providers of contact center services for Fortune 500 enterprises. Over the course of this 3-year contract, over $4,000,000 in revenues are expected to be generated by Pareteum.
Pareteum's Global Mobility Cloud Platform enables this Application Programming Interface (API)-driven contact center provider to seamlessly provide mobile connectivity to its Fortune 500 clients for online sales and marketing programs. This contract marks the fifth new customer Pareteum has signed for API connectivity since this new service was announced, and also represents the addition of call completion and messaging to the platform.
Transactional revenues will be received by Pareteum each time an application (app) developed on the customer's platform uses mobile connectivity to exchange content, complete communications, or monetize a transaction.
Hal Turner, Pareteum's Executive Chairman, commented, "Contact centers, formerly referred to as call centers, are today increasingly providing customer service, sales, and marketing by utilizing a wide range of technology and cloud-based services. In an increasingly customer-centric world, apps are being developed and deployed to serve Fortune 500 customers via contact centers. Having recently signed several contracts to provide global cloud connectivity for the API-economy, this contract marks our first customer in the global contact center market, which is projected to grow to $9.7 billion by 2019."
"We are very pleased to sign one of the leading contact center service providers in the world. This customer processes over 80 million messages monthly. These messages represent connections from thousands of enterprise contact centers that need to be mobile enabled. Pareteum's Global Mobility Cloud Platform is the perfect solution to provide seamless connectivity on any network, anywhere, anytime," stated Vic Bozzo, Pareteum's CEO.
About Pareteum Corporation
The mission of Pareteum Corporation (NYSE American: TEUM) is to connect "every person and everything." Organizations use Pareteum to energize their growth and profitability through cloud communication services and complete turnkey solutions featuring relevant content, applications, and connectivity worldwide. By harnessing the value of communications, Pareteum serves retail, enterprise, and IoT customers. Pareteum currently has offices in New York, Sao Paulo, Madrid, Barcelona, Bahrain, and the Netherlands. For more information, please visit: www.pareteum.com.
Image: https://www.accesswire.com/uploads/pareteum_logo.png
Forward-Looking Statements:
Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to Pareteum's plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about Pareteum's industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of Pareteum may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, Pareteum also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from those projected or suggested in Pareteum's filings with the Securities and Exchange Commission, copies of which are available from the SEC or may be obtained upon request from Pareteum Corporation.
Pareteum Investor Relations Contact:
Ted O'Donnell
Chief Financial Officer
(212) 984-1096
InvestorRelations@pareteum.com
SOURCE: Pareteum Corporation
(END) Dow Jones Newswires
September 21, 2017 08:15 ET (12:15 GMT)
Nice, $STAF 0.9199 0.0599 +6.97 548,032 0.90 0.92
On news,$JAGX 0.38 0.00 0.00 134,162 0.44 0.47
FDA Indicates That Jaguar's Canalevia Drug Product Candidate Qualifies as "Minor Use" for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication
28 minutes ago - DJNF
Jaguar Expects to Conduct the Commercial Launch of Canalevia in the First Half of 2018 for EID and CID (Chemotherapy-Induced Diarrhea) in Dogs, Dependent on Receiving Conditional Approval for These Indications
SAN FRANCISCO--(BUSINESS WIRE)--September 20, 2017--
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably-derived gastrointestinal products for both human prescription use and veterinary use on a global basis, announced today that the U.S. Food & Drug Administration's Center for Veterinary Medicine (CVM) has indicated that the use of Canalevia(TM) for treatment of exercise-induced diarrhea (EID) in dogs qualifies as a "minor use", per the requirements of The Minor Use and Minor Species Animal Health Act of 2004 (MUMS Act), which means that Canalevia(TM) is eligible for conditional approval for the indication of EID in dogs. Canalevia(TM) , Jaguar's lead veterinary drug product candidate, is under investigation for treatment of various types of diarrhea in dogs. EID is a distinct physiological manifestation that has been recorded in dogs, humans and horses.
"EID is a common problem among working dogs, such as sled dogs and military dogs, when subjected to periods of intense, long-duration off-leash exercise," Dr. Michael Guy, DVM, MS, PhD, Jaguar's vice president and clinical veterinarian, explained. "Several mammalian species that train for and run in competitive events can push themselves to extreme physical demands. At this highest level of physical exertion, secretory diarrhea is a common result, and the diarrhea can be debilitating enough to require medical attention and removal from competition or training. Diarrhea can have serious consequences for the canine athlete due to their high capacity for metabolic heat generation and reliance on evaporative cooling to dissipate heat."
"The best-known examples of these incredible canine athletes are those that participate in the Iditarod sled dog race--The Last Great Race--across Alaska every March. Teams of up to 16 dogs mush over 1,000 miles across Alaska in only 8-10 days, and approximately 40% of these dogs will experience severe diarrhea," commented Dr. Guy.
The purpose of the MUMS Act is to encourage development and availability of animal drugs intended as a minor use in a major species (defined as dogs, cats, cattle, horses, chickens, turkeys and pigs) to treat diseases which occur infrequently or in limited geographic areas, and to encourage development and availability of animal drugs for use in minor species (defined as all animals other than humans that are not one of the seven major species). MUMS designation is modeled on the orphan-drug designation for human drug development and offers possible financial incentives to encourage MUMS drug development, such as the availability of grants to help with the cost of developing the MUMS drug.
FDA established, and periodically reassesses, a specific "small number of animals" (defined as <1% of="" the="" total="" u.s.="" population="" of="" the="" specified="" species)="" for="" each="" of="" the="" seven="" major="" animal="" species="" in="" order="" to="" determine="" whether="" any="" particular="" intended="" use="" in="" a="" major="" species="" qualifies="" as="" a="" minor="" use.="" for="" dogs,="" this="" number="" is="" currently="" 70,000.="" jaguar="" believes="" canalevia(tm)="" will="" qualify="" for="" mums="" designation="" for="" eid="" because,="" in="" jaguar's="" estimate,="" the="" total="" number="" of="" dogs="" in="" the="" united="" states="" affected="" by="" eid="" on="" an="" annual="" basis="" is="" less="" than="" 70,000.="">
Jaguar has already received MUMS designation for Canalevia(TM) for use in dogs with chemotherapy-induced diarrhea (CID), which provides a possible opportunity to shorten the timeframe to commercialization for the CID indication. If Canalevia(TM) receives conditional approval for CID and EID in dogs, Jaguar expects to conduct the commercial launch of Canalevia(TM) for both indications in the first half of 2018.
Canalevia(TM) is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree, which is sustainably harvested. Canalevia(TM) is the subject of a previously announced collaboration between Jaguar and Elanco US Inc. (Elanco), a wholly-owned subsidiary of Eli Lilly. Per the terms of the agreement between Jaguar and Elanco, the two companies will collaborate on the global development of Canalevia(TM) for treatment of acute diarrhea in dogs, as well as on co-promotion and commercialization of Canalevia(TM) for the proposed indication of acute diarrhea in dogs in the U.S. Jaguar has retained commercial responsibility for the proposed CID and EID indications of Canalevia(TM) in dogs.
"We believe there is an important unmet medical need for the treatment of CID and EID in dogs," Lisa Conte, Jaguar's president and CEO, stated. "We believe Canalevia(TM) is an ideal treatment for both indications because of its demonstrated novel anti-secretory mechanism of action. Canalevia(TM) acts locally in the gut and is minimally absorbed systemically. It does not alter gastrointestinal motility, has no significant effects on normally-functioning intestinal ion channels or the transport of electrolytes or fluids, and has no side effects different from placebo. With regard to CID, these features are further augmented by the lack of effects of Canalevia(TM) on the absorption and/or metabolism of co-administered chemotherapy drugs, orally or by other routes of administration. Canalevia(TM) acts by normalizing the flow of excess ions and water in the intestinal lumen. The flow of excess ions and water into the intestinal lumen is the last step common to the manifestation of acute diarrhea. As a result, we believe Canalevia(TM) may be effective in the treatment of acute diarrhea, regardless of cause, including CID and EID."
To obtain conditional approval of a MUMS drug, the company must submit Chemistry, Manufacturing, and Controls (CMC) and safety data similar to that required for a new animal drug application (NADA) as well as data suggesting a reasonable expectation of effectiveness. After the submission and the review of the application, the FDA through the CVM can then grant a conditional approval (CA-1). This approval allows for commercialization of the product, while the sponsor continues to collect the substantial evidence of effectiveness required for a full NADA approval. A sponsor that gains approval or conditional approval for a MUMS-designated drug receives seven years of marketing exclusivity.
In June 2015 Jaguar completed a multi-site pilot safety study involving the anticipated commercial formulation of Canalevia(TM) for both CID and EID, and Jaguar expects to complete submission of all required major technical sections for the NADA for CID and EID to the FDA for phased review by the end of next month. Jaguar expects to receive FDA acknowledgment of the completion of all required technical sections in support of conditional approval of Canalevia(TM) in the first half of 2018 for CID and EID in dogs. With conditional approval under MUMS designation for Canalevia(TM) for use in dogs with EID, Jaguar would be required to initiate a pivotal field study in the five years following conditional approval to generate the data required for full NADA approval.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi(R) (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Mytesi(R) is in development for multiple possible follow-on indications, including chemotherapy-induced diarrhea; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease (IBD); irritable bowel syndrome (IBS); and as a second-generation anti-secretory agent for use in cholera patients. Canalevia(TM) is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. Equilevia(TM) is Jaguar's non-prescription product for total gut health in equine athletes. Canalevia(TM) and Equilevia(TM) contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm(TM) Calf and Neonorm(TM) Foal are Jaguar's lead non-prescription animal products. Mytesi(R) , Canalevia(TM) , Equilevia(TM) and Neonorm(TM) are distinct products that act at the same last step in a physiological pathway generally present in mammals.
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will conduct the commercial launch of Canalevia(TM) for the indications of CID and EID in the first half of 2018, the belief that Canalevia(TM) may be effective in the treatment of acute diarrhea, regardless of cause, including CID and EID, Jaguar's expectation that it will complete submission of all required major technical sections for the NADA for CID to the FDA for phased review by the end of next month, Jaguar's expectation that it will receive FDA acknowledgment of the completion of all required technical sections in support of conditional approval of Canalevia(TM) in the first half of 2018 for CID and EID in dogs, and the development of potential Mytesi(R) follow-on indications. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict,"
(MORE TO FOLLOW) Dow Jones Newswires
September 20, 2017 09:00 ET (13:00 GMT)
"potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20170920005740/en/
CONTACT: KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
SOURCE: Jaguar Health, Inc.
Copyright Business Wire 2017
(END) Dow Jones Newswires
September 20, 2017 09:00 ET (13:00 GMT)
FDA Indicates That Jaguar's Canalevia Drug -2-
"potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Jaguar-JAGX
View source version on businesswire.com: http://www.businesswire.com/news/home/20170920005740/en/
CONTACT: KCSA Strategic Communications
Garth Russell, 212-896-1250
grussell@kcsa.com
SOURCE: Jaguar Health, Inc.
Copyright Business Wire 2017
(END) Dow Jones Newswires
September 20, 2017 09:00 ET (13:00 GMT)
Thanks for the alerts, $STAF very low float!
Close watch, $NWBO 0.219 0.00 0.00 93,700 0.21 0.20
NW BIO Announces Registered Direct Offering Of $1.75 Million
25 minutes ago - DJNF
BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million.
In the transaction, the Company will sell approximately 8.75 million shares of common stock at a purchase price of $0.20 per share. Additionally, the investors will receive five year warrants to purchase up to approximately 4.375 million shares of common stock with an exercise price of $0.22 per share.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., acted as the exclusive placement agent for the transaction. The placement is expected to close on or about September 22, 2017, subject to satisfaction of customary closing conditions.
The securities described above are being offered pursuant to a shelf registration statement (File No. 333-213777), which was declared effective by the United States Securities and Exchange Commission ("SEC") on October 18, 2016. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request at H.C. Wainwright & Co. at placements@hcwco.com.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the North America and Europe. The Company has a broad platform technology for DCVax(R) dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM), which has completed its enrollment. GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." The Company is also pursuing a Phase I/II trial with DCVax-Direct for diverse inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion. The Company previously conducted a Phase I trial with DCVax-L for ovarian cancer.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company's ongoing ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company's products will demonstrate safety and efficacy, risks related to the Company's and Cognate's abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company's ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
View original content with multimedia:http://www.prnewswire.com/news-releases/nw-bio-announces-registered-direct-offering-of-175-million-300522771.html
SOURCE Northwest Biotherapeutics
/CONTACT: Les Goldman, 202-841-7909, lgoldman@nwbio.com
/Web site: http://www.nwbio.com
(END) Dow Jones Newswires
September 20, 2017 08:00 ET (12:00 GMT)
$ARGS 0.185 0.00 0.00 37,650 0.19 0.1998
? News, $ARGS 0.175 0.00 0.00 45,009 0.182 0.19
Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
51 minutes ago - DJNF
Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
DURHAM, N.C., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis(R) precision immunotherapy technology platform, will hold a conference call to discuss an update on the ongoing Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the treatment of metastatic renal cell carcinoma (mRCC) that was recently presented at the European Society for Medical Oncology (ESMO) 2017 Congress. Robert Figlin, MD, Professor and Chairman, Division of Hematology and Oncology at Cedars Sinai Medical Center and co-principal investigator for the ADAPT trial, delivered the oral presentation at the ESMO Conference and will participate in the call.
Conference Call and Webcast Details
Argos executive management will host the conference call beginning at 4:30 p.m. Eastern Time on Wednesday, September 20(th) . To participate by telephone, please dial the following numbers:
Domestic: (855) 433-0930
International: (484) 756-4271
The conference ID number is 88556647.
A live and archived audio webcast with the accompanying slide and video presentations will be accessible through the Investors section of the Company's website at www.argostherapeutics.com, and will remain available on the Company's website for twelve (12) months following the call.
In addition, the slides presented by Dr. Figlin at the ESMO Conference and a video in which Dr. Figlin discusses the trial will be posted to Argos' website at the time of the call.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis(R) technology platform. Argos' most advanced product candidate, Rocapuldencel-T, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). In addition, Rocapuldencel-T is being studied in a Phase 2 investigator-initiated clinical trial as neoadjuvant therapy for renal cell carcinoma (RCC). Argos is also developing a separate Arcelis(R) -based product candidate, AGS-004, for the treatment of human immunodeficiency virus (HIV), which is currently being evaluated in combination with vorinostat, a latency-reversing drug, in an investigator-initiated Phase 2 clinical trial aimed at HIV eradication in adult patients. Funding for the development of AGS-004 has been provided by the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and the Collaboratory of Research for AIDS Eradication.
Forward Looking Statements
Any statements in this press release about Argos' future expectations, plans and prospects, including statements about the ADAPT trial and the interim data from the trial, the clinical development of Argos' product candidates and future expectations and plans and prospects for Argos and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund its continuing operations for the period anticipated; whether preliminary or interim clinical data will be indicative of the final data from a clinical trial; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Argos' product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; whether Argos can successfully establish commercial manufacturing operations on a timely basis or at all; and other factors discussed in the "Risk Factors" section of Argos' Form 10-Q for the quarter ended June 30, 2017, which is on file with the SEC, and in other filings Argos makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent Argos' views as of the date hereof. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to the date hereof.
Investor contact:
Richard Katz, MD, MBA
Chief Financial Officer
Argos Therapeutics, Inc.
919-287-6315
rkatz@argostherapeutics.com
Media Contact:
Adam Daley
Berry & Company Public Relations
212.253.8881
adaley@berrypr.com
(END) Dow Jones Newswires
September 19, 2017 08:30 ET (12:30 GMT)
Thanks for the heads up, Welcome to the board.
Person marked you!
Glad i was chicken and sold @ .0029 $FUTL 0.0021 -0.0004 -16.00 190,035,326 0.002 0.0021
Close watch, Babcock & Wilcox Enterprises Inc
(NYSE : BW)
3.55 +0.34 ( 10.59%)
Read more at http://thestockmarketwatch.com/stock/?stock=BW#pRHEid1F0AJuJgzx.99